Market closedADR
Hutchmed/$HCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hutchmed
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Ticker
$HCM
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Hong Kong, Hong Kong
Employees
1,970
Website
Hutchmed Metrics
BasicAdvanced
$2.6B
-
-$0.05
0.76
-
Price and volume
Market cap
$2.6B
Beta
0.76
52-week high
$17.08
52-week low
$15.13
Financial strength
Current ratio
2.808
Quick ratio
2.656
Long term debt to equity
7.877
Total debt to equity
11.781
Interest coverage (TTM)
-159.16%
Management effectiveness
Return on assets (TTM)
-5.90%
Return on equity (TTM)
-5.44%
Valuation
Price to revenue (TTM)
21.495
Price to book
2.74
Price to tangible book (TTM)
2.74
Price to free cash flow (TTM)
-200.944
Growth
Revenue change (TTM)
-19.34%
Earnings per share change (TTM)
8.87%
3-year revenue growth (CAGR)
29.91%
3-year earnings per share growth (CAGR)
-41.69%
Hutchmed News
AllArticlesVideos
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
GlobeNewsWire·1 week ago
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Hutchmed stock?
Hutchmed (HCM) has a market cap of $2.6B as of March 14, 2025.
What is the P/E ratio for Hutchmed stock?
The price to earnings (P/E) ratio for Hutchmed (HCM) stock is 0 as of March 14, 2025.
Does Hutchmed stock pay dividends?
No, Hutchmed (HCM) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Hutchmed dividend payment date?
Hutchmed (HCM) stock does not pay dividends to its shareholders.
What is the beta indicator for Hutchmed?
Hutchmed (HCM) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.